GelSana is proud to announce that we have been awarded NIH SBIR Phase I funding through the NIDDK for the development of a hydrogel designed for the sustained delivery of an anti-inflammatory cytokine to treat diabetic foot ulcers. This significant milestone marks a transformative leap forward in our mission to redefine the future of wound care.

At GelSana, we understand the critical role that inflammation plays in the wound healing process. Our NIH SBIR Phase I project focuses on harnessing the power of a novel hydrogel formulation to deliver an anti-inflammatory molecule in a sustained manner. This approach has the potential to revolutionize how we manage wounds by modulating the inflammatory response to promote more efficient and effective healing.

GelSana is honored to collaborate with the National Institutes of Health through the SBIR program. This partnership underscores the potential impact of our hydrogel technology on advancing wound care practices and aligns with our commitment to innovation in the healthcare landscape. The successful completion of this NIH SBIR Phase I project is a significant step forward, setting the stage for subsequent phases of funding. GelSana is eager to continue refining and validating our hydrogel technology, working towards the ultimate goal of translating this innovation into real-world applications that benefit patients and healthcare providers alike.